People: Navidea Biopharmaceuticals Inc (NAVB.K)

NAVB.K on American Stock Exchange

1.27USD
22 Aug 2014
Price Change (% chg)

$0.01 (+0.79%)
Prev Close
$1.26
Open
$1.25
Day's High
$1.31
Day's Low
$1.25
Volume
334,402
Avg. Vol
875,608
52-wk High
$3.08
52-wk Low
$1.11

Search Stocks

Tulip, Thomas 

Brief Biography

Dr. Thomas H. Tulip, Ph.D. has been appointed as President, Chief Business Officer of Navidea Biopharmaceuticals, Inc., effective May 1, 2013. Prior to his appointment as President and Chief Business Officer, Dr. Tulip had served as Executive Vice President and Chief Business Officer of the Company since June 2011. Dr. Tulip has held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging, Bristol Myers Squibb (“BMS”) and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. Most recently, as President, Alseres Molecular Imaging, Dr. Tulip led efforts to develop markets for a Phase III neuroimaging agent. While at DuPont and BMS prior to Alseres, he was instrumental in the development, commercialization and international management of a nuclear cardiology franchise, built the BMS Medical Imaging international business, and led planning activities for innovative PET tracers at Lantheus/BMS. Dr. Tulip earned a B.S. from University of Vermont, and an M.S. and Ph.D. from Northwestern University. He was a visiting scholar at Osaka University and served as adjunct professor at Northeastern University. Dr. Tulip serves on the board of directors of the Medical Imaging Technology Association and leads its PET Working Group in the Molecular Imaging Section. He was recently Chairperson of the Institute for Molecular Technologies and held numerous leadership positions there. He served on the Board of the Academy of Molecular Imaging, including as its Treasurer. Dr. Tulip was Chairperson for the Society of Nuclear Medicine Corporate Advisory Board and has been active in a number of Council on Radionuclides and Radiopharmaceuticals committees, now serving on its Board of Directors.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
334,750 -- 396,260 731,010

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gordon Troup

--

Thomas Tulip

731,010

Michael Goldberg

--

Brent Larson

593,064

Frederick Cope

599,400

William Regan

--
As Of 30 Dec 2013
Search Stocks